LOS ANGELES--(BUSINESS WIRE)--Xcorporeal, Inc. and CT Holdings Enterprises, Inc. (OTCBB:CTHE) today announced that they have executed a definitive merger agreement with respect to a reverse triangular merger between Xcorporeal and CT Holdings, pursuant to which Xcorporeal will emerge as the surviving entity. Xcorporeal is a medical device company that has developed an innovative extra-corporeal platform technology to build devices that may potentially perform functions of various human organs. The four products that it plans to market are a hospital congestive heart failure (CHF) device; a hospital renal replacement device; a portable home hemodialysis device and a wearable artificial kidney.
